CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
High-concentration gadolinium nanoparticles for pre-clinical vascular imaging
Authors
Charmainne Cruje
Maria Drangova
Elizabeth R. Gillies
David W. Holdsworth
Publication date
1 January 2018
Publisher
'SPIE-Intl Soc Optical Eng'
Doi
Abstract
© 2018 SPIE. Gadolinium-based contrast agents that have long circulation times in small animals have always been of interest in preclinical imaging. Although gadolinium-based contrast media are used clinically in MRI, these agents are composed of small molecules; by renal clearance, these molecules exit the blood pool of small animals before imaging can be completed. Long circulation times that are appropriate for microimaging - in the order of tens of minutes - can be achieved by using nanoparticles that are large enough to evade rapid renal clearance (i.e. over 10 nm in diameter). The encapsulation of nanoparticles within polymers is also required to minimize their detection by the immune system, thus delaying hepatic clearance. Hence, the objective of our work was to develop a gadolinium-based contrast agent that will circulate long enough for pre-clinical computed tomography (CT) while maintaining blood pool detectability in the image (i.e. initial gadolinium content of around 100 mg/mL). We synthesized a contrast agent in the form of polymerencapsulated gadolinium nanoparticles by following a method that our group has reported. The nanoparticles in the contrast agent were characterized to have an average diameter of 110 ± 3 nm, and contains 94 ± 7 mg/mL of gadolinium. Our in vivo results in 2 mice show blood pool contrast enhancements of 220 ± 22 HU and circulates for up to an hour after tail vein injection. Given that the contrast agent stays in the blood pool of mice for up to an hour, the contrast agent has promising utility in pre-clinical vascular research
Similar works
Full text
Available Versions
Scholarship@Western
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:ir.lib.uwo.ca:biophysicspu...
Last time updated on 01/05/2021
Scholarship@Western
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:ir.lib.uwo.ca:boneandjoint...
Last time updated on 23/11/2020
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
info:doi/10.1117%2F12.2293016
Last time updated on 06/08/2021